Anteris Technologies Global Corp. (AVR)

Anteris Technologies Global Corp. is a structural heart company developing next-generation treatments for aortic stenosis. Its lead product candidate is DurAVR, a transcatheter aortic valve designed to mimic the shape and blood flow of a healthy native aortic valve, made from a single piece of bovine tissue.

The valve tissue is produced using the company's proprietary ADAPT anti-calcification tissue engineering process, which is intended to improve the durability of the implant. Anteris also develops the delivery system used to implant the valve and is conducting clinical studies to support regulatory approval.

Anteris has its U.S. headquarters in the Minneapolis area of Minnesota and significant operations in Brisbane, Australia. The company redomiciled to the United States and listed on Nasdaq in 2024.